The primary objective is to compare the efficacy of once daily (q.d.) subcutaneous (s.c.) injections of AVE5026 with placebo in the prevention of venous thromboembolism (VTE) in cancer patients at high risk for VTE and who are undergoing chemotherapy.

The secondary objectives are to evaluate the safety of AVE5026, to document AVE5026 exposures, to try identifying a metagene predictor of VTE and to assess the survival status at one year in this population.

Link to clinicaltrials.gov.au

Link to study protocol (login required)

2. The Sibling Cancer Needs Instrument (SCNI)

The primary objective is to identify psychosocial needs of sibling(s) of cancer patients via questionnaires. Sibling has to be aged 12-24 years and there is no age requirement of the cancer patient.

Contact person: Dr. Mark Wong

Contact number: 02 9845 5200